Vericel Q3 revenue $38.6M (+12% YoY); MACI $31M (+30%); net loss $6.6M; FY22 guidance $164-166M

Vericel Corp

2022-Q3 EPS reported -$0.48 revenue$111,671,000

Total net revenue $38.6M (+12% YoY); MACI net revenue $31.0M (+30% YoY); Epicel $7.3M; NexoBrid $0.2M.
Net loss of $6.6M ($0.14 per share) vs $4.9M loss in Q3 2021; adjusted EBITDA $3.3M.
Full-year 2022 guidance: total revenue $164-166M, MACI $130-132M, burn care ~$34M, gross margin mid-60%.
Cash and investments $133M, no debt; ninth straight quarter of positive adjusted EBITDA and operating cash flow.
NexoBrid BLA review progressing with FDA inspections; Type C meeting scheduled for MACI arthroscopic delivery.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.